[{"id":"897414a3-bc36-4d90-b0c6-902256e6b2d3","acronym":"","url":"https://clinicaltrials.gov/study/NCT02334865","created_at":"2021-02-24T21:53:04.763Z","updated_at":"2025-02-25T14:35:10.773Z","phase":"Phase 1","brief_title":"SVN53-67/M57-KLH Peptide Vaccine in Treating Patients With Newly Diagnosed Multiple Myeloma Receiving Lenalidomide Maintenance Therapy","source_id_and_acronym":"NCT02334865","lead_sponsor":"Roswell Park Cancer Institute","biomarkers":" HLA-A","pipe":" | ","alterations":" HLA-A*02 • HLA-A*24","tags":["HLA-A"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HLA-A*02 • HLA-A*24"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e lenalidomide • SurVaxM (SVN53-67/M57-KLH peptide vaccine) • Leukine (sargramostim)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 18","initiation":"Initiation: 04/13/2017","start_date":" 04/13/2017","primary_txt":" Primary completion: 09/16/2022","primary_completion_date":" 09/16/2022","study_txt":" Completion: 05/19/2026","study_completion_date":" 05/19/2026","last_update_posted":"2024-06-04"},{"id":"06d3177e-5a92-47e8-850d-071f514b294e","acronym":"SURVIVE","url":"https://clinicaltrials.gov/study/NCT05163080","created_at":"2021-12-20T16:53:58.249Z","updated_at":"2024-07-02T16:35:17.754Z","phase":"Phase 2","brief_title":"SurVaxM Plus Adjuvant Temozolomide for Newly Diagnosed Glioblastoma (SURVIVE)","source_id_and_acronym":"NCT05163080 - SURVIVE","lead_sponsor":"MimiVax, LLC","biomarkers":" IDH1 • MGMT • CD8","pipe":" | ","alterations":" IDH1 mutation","tags":["IDH1 • MGMT • CD8"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IDH1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e temozolomide • SurVaxM (SVN53-67/M57-KLH peptide vaccine)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 247","initiation":"Initiation: 11/18/2021","start_date":" 11/18/2021","primary_txt":" Primary completion: 08/18/2024","primary_completion_date":" 08/18/2024","study_txt":" Completion: 08/18/2024","study_completion_date":" 08/18/2024","last_update_posted":"2024-02-26"},{"id":"31ad4fb0-d303-4eae-8d17-c8dff89eabb4","acronym":"","url":"https://clinicaltrials.gov/study/NCT01250470","created_at":"2021-01-18T05:02:20.108Z","updated_at":"2024-07-02T16:37:24.983Z","phase":"Phase 1","brief_title":"Vaccine Therapy and Sargramostim in Treating Patients With Malignant Glioma","source_id_and_acronym":"NCT01250470","lead_sponsor":"Roswell Park Cancer Institute","biomarkers":" IFNG","pipe":" | ","alterations":" BIRC5 expression","tags":["IFNG"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BIRC5 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e SurVaxM (SVN53-67/M57-KLH peptide vaccine) • Leukine (sargramostim)"],"overall_status":"Completed","enrollment":" Enrollment 9","initiation":"Initiation: 09/05/2012","start_date":" 09/05/2012","primary_txt":" Primary completion: 05/29/2014","primary_completion_date":" 05/29/2014","study_txt":" Completion: 05/29/2014","study_completion_date":" 05/29/2014","last_update_posted":"2017-02-27"}]